WEITZMAN DEBORAH
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to WEITZMAN DEBORAH. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| CAH | CEO, PSS Segment | Tax Withholding | 551 | $212.26 | $116,955 | Dec 1, 2025 |
| CAH | CEO, PSS Segment | Sale | 21,367 | $150.53 | $3,216,375 | Aug 20, 2025 |
| CAH | CEO, PSS Segment | Award / Grant | 10,694 | — | — | Aug 15, 2025 |
| CAH | CEO, PSS Segment | Award / Grant | 39,100 | — | — | Aug 12, 2025 |
| CAH | CEO, PSS Segment | Tax Withholding | 632 | $122.24 | $77,256 | Dec 2, 2024 |
| CAH | CEO, PSS Segment | Award / Grant | 13,530 | — | — | Aug 15, 2024 |
| CAH | CEO, PSS Segment | Award / Grant | 13,926 | — | — | Aug 13, 2024 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 638 | $107.08 | $68,317 | Dec 1, 2023 |
| CAH | CEO, Pharmaceutical Segment | Option Exercise | 5,990 | $84.27 | $504,777 | Nov 27, 2023 |
| CAH | CEO, Pharmaceutical Segment | Option Exercise | 6,712 | $71.43 | $479,438 | Aug 28, 2023 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 10,966 | $92.99 | $1,019,728 | Aug 16, 2023 |
| CAH | CEO, Pharmaceutical Segment | Award / Grant | 12,760 | — | — | Aug 7, 2023 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 380 | $80.17 | $30,465 | Dec 1, 2022 |